CMS To Test Value-Based Insurance Design; Diabetes, COPD Among Target Diseases
This article was originally published in RPM Report
The pharmaceutical industry should welcome a test of VBID that will begin in 2017. While it focuses primarily on disease areas with high generic drug usage, it nevertheless can help demonstrate that assuring greater use of pharmaceuticals can be cost effective – offering a nice counter to the relentless focus on drug pricing as a negative.
Register for our free email digests: